申请人:Glaxo Group Limited
公开号:US05019586A1
公开(公告)日:1991-05-28
The present invention provides ketones of the general formula (I): ##STR1## and physiologically acceptable salts and solvates thereof, wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-6 alkyl group; Im represents an imidazolyl group of formula: ##STR2## wherein one of the groups represented by R.sup.3, R.sup.4 and R.sup.5 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenylC.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkyl group; and p0 A is a group of the formula (a), (b), (c), (d), (e), (f) or (g): ##STR3## and when A is the group (g), the group --COCR.sup.1 R.sup.2 CH.sub.2 Im is attached at the 2- or 4- position of the indole moiety. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety and nausea and vomiting.
本发明提供了一般式(I)的酮类化合物:##STR1##以及其生理学上可接受的盐和溶剂化物,其中R.sup.1和R.sup.2,可以相同也可以不同,分别代表氢原子或C.sub.1-6烷基;Im代表式为:##STR2##的咪唑基,其中由R.sup.3、R.sup.4和R.sup.5代表的三个基中的一个是氢原子或C.sub.1-6烷基、C.sub.3-7环烷基、C.sub.3-6烯基、苯基或苯基C.sub.1-3烷基,而另外两个基,可以相同也可以不同,分别代表氢原子或C.sub.1-6烷基;p0 A是式(a)、(b)、(c)、(d)、(e)、(f)或(g)的基团:##STR3##当A是基团(g)时,基团--COCR.sup.1 R.sup.2 CH.sub.2 Im附着在吲哚基团的2-或4-位置。这些化合物是5-HT.sub.3受体的有效和选择性拮抗剂,例如在治疗精神疾病、焦虑和恶心呕吐方面有用。